Who is generally a candidate Adults 18 and older with a BMI of 30 or higher (obesity), or Adults with a BMI of 27 or higher plus at least one weight-related condition: type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea No disqualifying personal or family medical history (see below) Willing to attend an in-person evaluation and follow-up visits during titration Who we generally do not prescribe to Personal or family history of medullary thyroid carcinoma or MEN2 syndrome (multiple endocrine neoplasia type 2) History of pancreatitis Severe gastroparesis or other significant gastrointestinal motility disease Pregnancy , breastfeeding, or actively planning pregnancy An active eating disorder Known hypersensitivity to semaglutide, tirzepatide, or a formulation's inactive ingredients We also look at what else is driving your case before deciding a GLP-1 is the right tool
Quick Answer: Brain fog is not listed as an official adverse reaction to Wegovy in UK prescribing information, though some individuals report cognitive symptoms that may relate to dietary changes, dehydration, or metabolic factors rather than the medication itself
Gradual Weight Loss Microdosing semaglutide might result in more gradual weight loss over a longer period of time
Tirzepatide is a dual GLP-1 and GIP agonist that activates two hormone pathways, producing greater weight loss than semaglutide
When you begin Semaglutide GLP-1 treatment , it usually takes about two weeks for the medication to start working in your body
It has been linked to the modulation of various stress-related pathways and is believed to play a pivotal role in cellular adaptation
